A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design

Table 1 Characteristics of eligible HIV/Hepatitis C interventional trials, ClinicalTrials.gov registry, 2007 to 2010 (N = 477)

Characteristic	N	% or IQR
Primary Sponsor
Non-industry	298	62.5
Industry	179	37.5
Allocation^a
Non-Randomized	140	29.4
Randomized	329	69.0
Overall status
Not yet recruiting	41	8.6
Recruiting	206	43.2
Active not currently recruiting	123	25.8
Completed	94	19.7
Terminated	13	2.7
Number of participants^a
Median (IQR)	80	36, 179
Less than or equal to 100	288	60.4
101 to 1,000	173	36.3
Greater than 1,000	14	2.9
Start year^a
Before 2007	63	13.2
2007	42	8.8
2008	130	27.3
2009	137	28.7
2010	98	20.6
Phase
2/3	284	59.5
4	193	40.5
Study has DMC^ab
No	207	43.4
Yes	189	39.6
Excludes > 65 years
No	352	73.8
Yes	125	26.2
Number of study sites^a
Single facility	205	43.0
Multiple facilities	225	47.2
Foreign sites
No	126	26.4
Yes	351	73.6
Condition
Hepatitis C (HCV)	156	32.7
HIV/AIDS	304	63.7
HCV + HIV/AIDS	17	3.6

^aTotals for each variable may not add up to 100 % secondary to observations with missing data.
^bDMC = data monitoring committee. IQR = interquartile range.

ISSN: 1745-6215